Experimental designs for phase I and phase I/II dose-finding studies.
about
Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trialsAplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical TrialsLenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Current issues in oncology drug development, with a focus on Phase II trialsQuality assessment of phase I dose-finding cancer trials: proposal of a checklist.Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropoutsIncorporating lower grade toxicity information into dose finding designs.The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.Interplay of priors and skeletons in two-stage continual reassessment method.A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.A robust Bayesian dose-finding design for phase I/II clinical trials.Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.Small-sample behavior of novel phase I cancer trial designs.Estimating the dose-toxicity curve in completed phase I studies.Design considerations for dose-expansion cohorts in phase I trialsContinual reassessment and related designs in dose-finding studies
P2860
Q27023178-832DE254-33E4-4C98-BE0B-0110F3E05839Q28552571-32E95C89-053A-43CB-82A5-65170099A223Q33408772-D6CD2993-6831-426C-BA62-9BAB9C2C2C6AQ33433456-1C86E0DC-B0D6-400F-822D-A6EFA0F01A0CQ33644414-E86870E6-2900-4FA4-9145-668848C052ECQ33772533-09D82C63-2231-4468-9CB2-085D3A5DDB56Q35328870-91B54A1A-7A70-4B81-B201-D733125EA7B6Q35800784-9DB6F5FA-3E51-45D4-BF4E-2B072857890AQ36295897-0411982C-F808-483E-9F11-F62FFBF05F15Q36513919-F270BAA5-4E79-4821-B3D6-C5E70E140BB3Q36612188-4CB1C2B9-385F-4F53-9CD6-721DA86F1B99Q37220245-1267EAEA-8F1A-4718-9312-7F40CD0E3C21Q37523183-1190BA93-A088-4DD1-B62F-6E466291BC39Q39479987-2FC77E4F-532C-4E7E-8C97-C80F4EBE2005Q40764278-8AB29C19-ACDB-4E85-9918-A67F66482B0AQ41895594-2C015DE0-8972-43A3-B8DD-F14C2BB075A8Q42172755-631CCA77-D9AE-430E-B25B-1F4F9D1E8FF9
P2860
Experimental designs for phase I and phase I/II dose-finding studies.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Experimental designs for phase I and phase I/II dose-finding studies.
@ast
Experimental designs for phase I and phase I/II dose-finding studies.
@en
type
label
Experimental designs for phase I and phase I/II dose-finding studies.
@ast
Experimental designs for phase I and phase I/II dose-finding studies.
@en
prefLabel
Experimental designs for phase I and phase I/II dose-finding studies.
@ast
Experimental designs for phase I and phase I/II dose-finding studies.
@en
P2860
P356
P1476
Experimental designs for phase I and phase I/II dose-finding studies.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602969
P407
P577
2006-03-01T00:00:00Z
2006-03-13T00:00:00Z
P5875
P6179
1013557227